Mayor Rob Ford, shown in this file photo, has received news that the tumor in his abdomen has shrunk as a result of chemotherapy treatment. - Staff file photo/DAVID NICKLE
Mayor Rob Ford, shown in this file photo, has received news that the tumor in his abdomen has shrunk as a result of chemotherapy treatment. - Staff file photo/DAVID NICKLE
That was the word from Mount Sinai Hospital, where the former mayor was undergoing the latest round of chemotherapy this week to battle the aggressive cancer that was discovered in his abdomen this past summer.
The diagnosis caused Ford to drop out of the mayor’s race and run instead for his own seat on council, as he underwent chemotherapy.
ARTICLE CONTINUES BELOW
Until now, the results from those sessions weren’t encouraging: while the tumor was arrested in its growth, it didn’t get any smaller — a prerequisite for surgery.
Outside the hospital on Tuesday, Dec. 16,, Rob’s brother Doug Ford – who ran unsuccessfully for mayor in Rob’s place – delivered the good news to reporters after he and Rob received it.
"(Rob) was ecstatic but there’s only so much you can be ecstatic for," said Doug Ford.
"You still have cancer, you still have a long journey, we aren’t celebrating yet. But it’s the first positive news we’ve had in six weeks."
ARTICLE CONTINUES BELOW
Doug Ford said doctors will likely perform another MRI to decide what to do next, but he said it was likely that Ford would undergo radiation therapy before attempting surgery to remove the growth.
Anyone can read Conversations, but to contribute, you should be a registered Torstar account holder. If you do not yet have a Torstar account, you can create one now (it is free).
To join the conversation set a first and last name in your user profile.
Anyone can read Conversations, but to contribute, you should be a registered Torstar account holder. If you do not yet have a Torstar account, you can create one now (it is free).
To join the conversation set a first and last name in your user profile.
Sign in or register for free to join the Conversation